Insulin Calculator Cleared; Twice-Rejected Diabetes Drug; Ozempic for Alcohol Use?

— News and commentary from the endocrinology world

Endo Break over a computer rendering of a man with illustrated body organs.

The FDA cleared the digital diabetes health platform BlueStar, featuring a continuous glucose monitoring-informed bolus insulin dose calculator, developer Welldoc announced.

The agency also cleared Roche's Accu-Chek Solo micropump system -- a tubing-free pump for insulin users.

Several phased-out flame retardants and new endocrine-disrupting replacement chemicals were found in the breast milk of mothers. (NPR)

Third times the charm? An FDA advisory committee is convening in a few weeks to once again discuss Intarcia's type 2 diabetes drug ITCA 650 after it was already rejected twice. (Endpoints News)

Certain cardiorenal stress biomarkers were found to be "strongly prognostic" in patients with type 2 diabetes and albuminuria, said researchers in Circulation.

The risk of developing gestational diabetes was similar for those who received group versus individual prenatal care. (JAMA Network Open)

Some individuals say semaglutide (Ozempic, Wegovy) has curbed their cravings for alcohol. (NPR)

Europe will continue to have a shortage of diabetes drugs through September, the European Medicines Agency said. (Reuters)

Researchers at University of California San Diego received a $2 million grant to study liver-targeted insulin therapy.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.